Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
June 6, 2024
- PeptiDream Doses 1st Patient with CA9-Targeted Radiopeptide
June 6, 2024
- Japan Vaccine Market Projected to Top 280 Billion Yen in FY2024: Fuji Keizai
June 6, 2024
- PharmaEssentia’s Besremi Gets Health Coverage for Self-Injection
June 5, 2024
- China Outpaces US in Oncology Trials, Japan’s Share Sags: IQVIA
June 5, 2024
- Twymeeg Tops April GP Rep Promotion Rankings: Intage
June 5, 2024
- Lilly’s Ulcerative Colitis Therapy Omvoh Now Available for Self-Injection
June 4, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Organon Launches Fertility Med Follistim after Re-Submission
June 4, 2024
- EU Panel OKs Adzynma for cTTP under Exceptional Circumstances
June 4, 2024
- Janssen Files Amivantamab for Post-Tagrisso NSCLC Setting in Japan
June 3, 2024
- Bayer, Kyoto University Form Strategic Alliance to Fuel Innovation
June 3, 2024
- Tapinarof Cream Hits Main Goal in PIII Eczema Trial in Children: JT/Torii
June 3, 2024
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
- Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…